Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · IEX Real-Time Price · USD
6.96
-0.24 (-3.33%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Revenue
Actinium Pharmaceuticals had revenue of $81.00K in the twelve months ending March 31, 2024, down -10.00% year-over-year. In the year 2023, Actinium Pharmaceuticals had annual revenue of $81.00K, a decrease of -92.14%.
Revenue (ttm)
$81.00K
Revenue Growth
-10.00%
P/S Ratio
2,559.17
Revenue / Employee
$1,653
Employees
49
Market Cap
207.29M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 81.00K | -949.00K | -92.14% |
Dec 31, 2022 | 1.03M | -114.00K | -9.97% |
Dec 31, 2021 | 1.14M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Codexis | 74.23M |
NeuroPace | 69.07M |
AVITA Medical | 51.50M |
Senseonics Holdings | 23.30M |
Profound Medical | 5.33M |
Fractyl Health | 148.00K |
ATNM News
- 15 days ago - Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML) - Newsfile Corp
- 15 days ago - Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress - PRNewsWire
- 18 days ago - Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial - PRNewsWire
- 21 days ago - Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting - PRNewsWire
- 22 days ago - Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting - PRNewsWire
- 6 weeks ago - Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity - PRNewsWire
- 7 weeks ago - Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial - PRNewsWire
- 7 weeks ago - Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting - PRNewsWire